Selecta Biosciences (SELB) vs. Its Rivals Head to Head Survey

Selecta Biosciences (NASDAQ: SELB) is one of 286 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Selecta Biosciences to related companies based on the strength of its institutional ownership, earnings, analyst recommendations, risk, valuation, dividends and profitability.

Valuation and Earnings

This table compares Selecta Biosciences and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Selecta Biosciences $8.08 million -$36.21 million -3.24
Selecta Biosciences Competitors $284.49 million $34.10 million 59.71

Selecta Biosciences’ competitors have higher revenue and earnings than Selecta Biosciences. Selecta Biosciences is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Selecta Biosciences and its competitors, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Selecta Biosciences 0 0 2 0 3.00
Selecta Biosciences Competitors 888 3274 11773 235 2.70

Selecta Biosciences presently has a consensus price target of $29.00, indicating a potential upside of 188.84%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 42.50%. Given Selecta Biosciences’ stronger consensus rating and higher probable upside, equities analysts clearly believe Selecta Biosciences is more favorable than its competitors.


This table compares Selecta Biosciences and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Selecta Biosciences -1,918.59% -100.06% -61.41%
Selecta Biosciences Competitors -5,211.48% -209.11% -37.70%

Insider & Institutional Ownership

54.4% of Selecta Biosciences shares are held by institutional investors. Comparatively, 49.9% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 41.9% of Selecta Biosciences shares are held by company insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.


Selecta Biosciences beats its competitors on 7 of the 12 factors compared.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its product candidates are in various stages of clinical and preclinical development. Its SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. The Company’s lead product candidate, SEL-212, is a combination of a therapeutic enzyme and its SVP technology designed to be the biologic treatment for gout.

Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with's FREE daily email newsletter.

Leave a Reply